Chemoprevention in Barrett's esophagus: A pill a day?
Esophageal adenocarcinoma is increasing in incidence. The main risk factor is the premalignant condition of Barrett's esophagus. There is great interest in chemoprevention to prevent or slow malignant transformation. There are many agents proposed as playing a role in chemoprevention; however, none is licensed for this role as yet. Aspirin possesses many favorable qualities for chemoprevention and is the focus of the largest randomized control trial in this field.
Digestive Diseases Centre, Leicester Royal Infirmary, Infirmary Square, Leicester, LE1 5WW, UK. j.a.jankowski@qmul.ac.uk
Janusz A
JA
Jankowski
Patricia A
PA
Hooper
D000230:Adenocarcinoma / Q000517:prevention & control*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001471:Barrett Esophagus / Q000473:pathology / Q000517:prevention & control*; D004032:Diet; D004938:Esophageal Neoplasms / Q000517:prevention & control*; D006801:Humans; D011230:Precancerous Conditions / Q000473:pathology / Q000517:prevention & control*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D054328:Proton Pump Inhibitors; D001241:Aspirin